Healthcare Stocks

Imugene Limited (ASX:IMU) Progressing with PD1-Vaxx Phase I Trial

 Imugene Limited (ASX:IMU) Progressing with PD1-Vaxx Phase I Trial

Summary Imugene Limited (ASX:IMU) completes the enrolment of three patients under the first cohort under PD1-Vaxx Phase I clinical trial. Following the Phase I trial, a monotherapy optimal biological dose will be determined through a review by ...

Read More...
Imugene Reports Impressive B-cell vaccines Data at ESMO Congress 2019

Imugene Reports Impressive B-cell vaccines Data at ESMO Congress 2019

Australian-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX: IMU) is engaged towards the development of several new and novel immunotherapies that work to activate the cancer patients? immune system to treat and remove tumours....

Read More...
Imugene Progressing Rapidly With Its Strong Product Pipeline; Glimpse At Stock’s Technical Analysis

Imugene Progressing Rapidly With Its Strong Product Pipeline; Glimpse At Stock’s Technical Analysis

Clinical stage immuno-oncology player headquartered in Australia, Imugene Limited (ASX: IMU) is engaged in the development of several new and unique immunotherapies that work to trigger the cancer patients? immune system to treat and remove tumours. ...

Read More...
Immuno-Oncology Market Player, Imugene Delivers Remarkable Performance In FY 2019

Immuno-Oncology Market Player, Imugene Delivers Remarkable Performance In FY 2019

Clinical stage immuno-oncology firm headquartered in Australia, Imugene Limited (ASX: IMU) is engaged in the development of a wide range of new treatments that attempt to activate the cancer patients? immune system to detect and remove tumours. Imuge...

Read More...
A Deep Dive into Imugene’s Opportunities in the Immuno-oncology Market

A Deep Dive into Imugene’s Opportunities in the Immuno-oncology Market

Imugene Limited (ASX: IMU) is a clinical stage biotechnology company that focuses on the development of immunotherapies that have the potential to enable a patient?s immune system to recognise and destroy cancer cells. The company is focused on targe...

Read More...
Imugene Goes Great Guns with Strong Management Team

Imugene Goes Great Guns with Strong Management Team

Imugene Limited (ASX: IMU), an Australian-headquartered clinical-stage immuno-oncology company, focusses on the development of emerging immunotherapies to enhance the efficacy of cancer treatments. The company utilises its unique platform technology ...

Read More...
A Glance at Imugene’s B-Cell Vaccine Developments in 2019

A Glance at Imugene’s B-Cell Vaccine Developments in 2019

An Australian-headquartered clinical stage biotechnology company, Imugene Limited (ASX: IMU) seeks to develop different novel immunotherapies to boost the efficacy of cancer treatments. Imugene?s product pipeline covers oncolytic viruses and several ...

Read More...
Imugene Releases Bioshares Presentation and Quarterly Updates; Stock Zooms up

Imugene Releases Bioshares Presentation and Quarterly Updates; Stock Zooms up

An emerging leader in cancer immuno-oncology, Imugene Limited (ASX: IMU) is a clinical stage biotechnology company seeking to develop a range of novel immunotherapies to enhance the efficacy of cancer treatments. Imugene has released its Quarterly A...

Read More...
An Overview Of IMU’s B-Cell Vaccines’ Clinical Trials

An Overview Of IMU’s B-Cell Vaccines’ Clinical Trials

An Australian-based biotechnology company, Imugene Limited (ASX: IMU) focuses on the development of cancer immunotherapies targeted at activating the immune system of cancer patients. The company?s exceptional platform technology helps in stimulating...

Read More...
Imugene Expands Immunotherapy Platform, Announces Licensing of Oncolytic Virus CF33 from City of Hope Cancer Centre

Imugene Expands Immunotherapy Platform, Announces Licensing of Oncolytic Virus CF33 from City of Hope Cancer Centre

A biotech company headquartered in Australia, Imugene Limited (ASX: IMU) develops new and novel immunotherapies that seek to harness the cancer patients? immune system against tumors. The company?s unique platform technologies seeks to potentially ac...

Read More...
Imugene Presents New HER-Vaxx Data At ESMO World Congress On Gastrointestinal Cancer

Imugene Presents New HER-Vaxx Data At ESMO World Congress On Gastrointestinal Cancer

A biotechnology company listed on the Australian Stock Exchange (ASX), Imugene Limited (ASX: IMU) develops cancer immunotherapies targeting B-cell peptide vaccines. The immunotherapies developed by the company seek to activate the cancer patients? im...

Read More...
Ad

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK